Lee Frank D.'s Form 4 filing
Forma Therapeutics Holdings, Inc.FMTX · filed Feb 25, 2022
- Accession no.
- 0000899243-22-007923
- Filed
- Feb 25, 2022
- Trade date
- Feb 23, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $175.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lee Frank D.CIK 0001814686 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 23, 2022 | Common Stock | SSaleDisposed | −17,981 | $9.78F2 | −$175,854.18 | 79,769 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.61 to $10.005. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
In a Form 4 filed by the reporting person on March 2, 2021, the box indicating "no longer subject to Section 16" was inadvertently checked. The reporting person has remained subject to Section 16, and all changes in beneficial ownership subsequent to such Form 4 have been properly reported on a timely basis.